Table 3.
Combined detection | AUC | Sensitivity (%) | Specificity (%) | 95% CI | PPV (%) | NPV (%) |
---|---|---|---|---|---|---|
Two-item in combination | ||||||
QFT + ESR | 0.804 | 76.71 | 77.04 | 0.745-0.863 | 64.4 | 86.0 |
QFT + serum ADA | 0.823 | 90.41 | 69.63 | 0.767-0.879 | 61.7 | 93.1 |
QFT + serum CA125 | 0.830 | 76.71 | 81.48 | 0.774-0.886 | 69.1 | 86.6 |
QFT + hs − CRP | 0.844 | 83.56 | 78.52 | 0.789-0.898 | 67.8 | 89.8 |
Three-item in combination | ||||||
QFT + ESR + serum ADA | 0.816 | 87.67 | 68.15 | 0.759-0.873 | 59.8 | 91.1 |
QFT + ESR + serum CA125 | 0.814 | 90.41 | 63.70 | 0.758-0.871 | 57.4 | 92.5 |
QFT + ESR + hs − CRP | 0.840 | 87.67 | 74.81 | 0.785-0.894 | 65.3 | 91.8 |
QFT + serum ADA + serum CA125 | 0.823 | 89.04 | 71.11 | 0.767-0.879 | 62.5 | 92.3 |
QFT + serum ADA + hs − CRP | 0.858 | 95.89 | 64.44 | 0.808-0.908 | 59.3 | 96.7 |
QFT + serum CA125 + hs − CRP | 0.851 | 91.78 | 70.37 | 0.798-0.904 | 62.6 | 94.1 |
Four-item in combination | ||||||
QFT + ESR + serum ADA + serum CA125 | 0.819 | 83.56 | 69.63 | 0.763-0.875 | 59.8 | 88.7 |
QFT + ESR + serum ADA + hs − CRP | 0.857 | 91.78 | 69.63 | 0.807-0.908 | 62.0 | 94.0 |
QFT + serum ADA + serum CA125 + hs − CRP | 0.858 | 83.56 | 76.30 | 0.807-0.908 | 65.6 | 89.6 |
QFT + ESR + serum CA125 + hs − CRP | 0.849 | 84.93 | 76.30 | 0.796-0.901 | 66.0 | 90.4 |
Five-item in combination | ||||||
QFT + ESR + serum ADA + serum CA125 + hs − CRP | 0.859 | 97.26 | 62.96 | 0.809-0.909 | 58.7 | 97.7 |
Note: Comparison of AUCs of two-item in combination, p > 0.05; comparison of AUCs of three-item in combination, p > 0.05; comparison of AUCs of four-item in combination, p > 0.05. PPV: positive predictive value; NPV: negative predictive value; AUC: area under the curve; QFT: Quanti FERON-TB; ESR: erythrocyte sedimentation rate; ADA: adenosine deaminase; CA125: cancer antigen 125; hs-CRP: high-sensitivity C-reactive protein.